| Introduction | 4 |
| Grant Programmes 2007: | |
| **EFSD** | 6 |
| Clinical Research Grants | |
| **EFSD/Amylin** | 7 |
| Paul Langerhans Grant on the Integrated Physiology of the Entero-Insular Axis and the Brain in Metabolic Homeostasis | |
| **EFSD Grant Award** | 8 |
| Collaborative Diabetes Research between China and Europe supported by **Bristol-Myers Squibb Company (BMS)** | |
| **EFSD/GlaxoSmithKline** | 9 |
| Programme for the Study of Metabolic Toxicity in Diabetes | |
| **EFSD/JDRF/Novo Nordisk** | 10 |
| European Programme in Type 1 Diabetes Research | |
| **EFSD/LifeScan** | 12 |
| European Studies on Glucose Monitoring | |
| **EFSD/Lilly** | 13 |
| European Diabetes Research Programme | |
| **EFSD/Merck Sharp & Dohme (MSD)** | 14 |
| European Studies on Beta Cell Function and Survival | |
| **EFSD/Novartis** | 15 |
| European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction | |
| **EFSD/Novo Nordisk** | 16 |
| European Clinical Research Programme in Adolescents with Type 2 Diabetes | |
| **EFSD/sanofi-aventis** | 17 |
| European Programme: The Endocannabinoid System from Bench to Bedside and European Programme: Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease | |
| **EFSD/Servier** | 19 |
| European Research Programme on Vascular Complications of Type 2 Diabetes | |
# Fellowships and Awards 2007:

**Albert Renold Fellowships**
supported by **Merck Sharp & Dohme (MSD)**

**EFSD/AstraZeneca**
Young Investigator Awards

**EFSD Travel Fellowships for Young Researchers from China**
supported by **Bristol-Myers Squibb Company (BMS)**

**EFSD/Lilly**
Research Fellowships in the Fields of Metabolism and Complications of Diabetes

**EFSD/Pfizer**
Resource Awards for Diabetes Research

---

# New Programmes 2008:

**EFSD/Chinese Diabetes Society/Lilly**
Collaborative Diabetes Research Programme

**EFSD/Merck Sharp & Dohme (MSD)**
European Studies on Islet Cell Function and Survival:
Clinical Research Programme

**EFSD/Pfizer**
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes

*Note: the above relates solely to programmes which have been officially agreed to date.*
In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

**Partnerships bring over Euro 48 Million to European diabetes research**

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over Euro 48 million to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the web site of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country.
Clinical Research Grants

Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of type 2 diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. In 2008, the focus will be broadened in order to fund clinical research into any aspect of type 1 and type 2 diabetes.

Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme will commit a total of Euro 2.4 million towards clinical research in diabetes, with awards of up to Euro 300,000 over a period of up to three years, dependent upon the needs of the project.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 300,000:

Peter Karl Jacobsen: Steno Diabetes Center - Gentofte, Denmark
Valeriya Lyssenko: Lund University - Malmö, Sweden
Monica Nannipieri: University of Pisa – Italy
Gianluca Perseghin: CORIPREMEND - Milano, Italy
Paul Langerhans Grant on the Integrated Physiology of the Entero-Insular Axis and the Brain in Metabolic Homeostasis

Background

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development. Amylin currently has two first in class diabetes drugs approved and marketed in the United States.

This grant honours the memory of Paul Langerhans, who discovered the islet cells of the pancreas.

Plan

EFSD and Amylin established a partnership in 2005 to provide grants of up to Euro 100,000 for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis. The Programme’s goal is to encourage new projects aimed at advancing current knowledge, and to stimulate and accelerate European research in this domain.

Funding Instruments

Since its creation in 2005 and with additional funds committed in 2007, the total funding commitment of the partnership is now Euro 700,000, made available as research grants.

Awards in 2007

No grant was awarded in 2007. However, the EFSD/Amylin partnership intends to make available Euro 500,000 in 2008.
Plan

EFSD established the Grant Awards for Collaborative Diabetes Research between China and Europe to encourage new projects aimed at advancing current knowledge in this domain and to support diabetes research. These EFSD Grant Awards are intended to stimulate and accelerate the co-operation between researchers in China and Europe for research into diabetes.

The projects are to be carried out in China, but performed in co-operation with a European research centre.

Funding Commitment and Instruments

This Programme was established in 2006 with renewal in 2007, bringing the total amount committed to date to Euro 400,000 for grants of up to Euro 50,000.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 50,000:

Weiping Jia: Shanghai Diabetes Institute, collaborating with the Oxford Centre for Diabetes - UK
Ying Liu: Peking Union Medical College, collaborating with Karolinska Institutet – Stockholm, Sweden
Shuixian Shen: Fudan University, collaborating with Karolinska Institutet - Stockholm, Sweden
Hongbin Sun: China Pharmaceutical University, collaborating with the University of Newcastle - UK
Qihua Tan: Qingdao University, collaborating with Odense University Hospital - Denmark
EFSD
and
GlaxoSmithKline

Programme for the Study of Metabolic Toxicity in Diabetes

**Background**

Headquartered in the UK, and with operations based in the US, GlaxoSmithKline are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. Their mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

**Plan**

EFSD and GlaxoSmithKline have established a new partnership intended to stimulate and accelerate European research aimed at all aspects of metabolic cytotoxicity, with particular focus on molecular mechanisms of glucotoxicity and lipotoxicity, the mechanism of dysfunction and death of islet cells induced by hyperglycaemia and/or dyslipidaemia and the mechanism of insulin resistance induced by hyperglycaemia and/or dyslipidaemia.

**Funding Commitment and Instruments**

Established in 2007 and since renewed, the total commitment of this partnership is **Euro 1 million**, made available as grants each of up to Euro 100,000.

**Awards in 2007**

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

- Christophe Magnan: CNRS Université Paris 7 – France
- Lorella Marselli: University of Pisa – Italy
- Claudia Miele: CNR Naples – Italy
- Giovambattista Pani: Università Cattolica del Sacro Cuore – Rome, Italy
- Michael Roden: University of Vienna – Austria
European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The partners have renewed the EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

Funding Commitment and Instruments

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has since been renewed twice, with a combined commitment of Euro 11.75 million. Grants of up to Euro 100,000, are available each year.
Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Isabella Artner: Lund University – Malmö, Sweden
Malin Flodström-Tullberg: Karolinska Institutet - Stockholm, Sweden
Roberto Mallone: Hôpital Necker Paris - France
Jens Nielsen: University of Copenhagen - Denmark
Suvi M. Virtanen: University of Tampere - Finland
European Studies on Glucose Monitoring

Background

For more than two decades LifeScan has been committed to improving the quality of life for people with diabetes. LifeScan helped bring blood glucose testing out of the laboratory and into the hands of patients.

Plan

The EFSD/LifeScan Awards are intended to stimulate and accelerate European research aimed at improved understanding of the optimal use of glucose monitoring tools, both in type 1 and type 2 diabetes.

Commitment and Instruments

The partnership was launched in 2005, and with additional funding in 2007, has committed a total of Euro 1.2 million, offered in the form of research grants.

Awards in 2007

No grant was awarded in 2007. However, the EFSD/LifeScan partnership will make available Euro 500,000 in 2008.
EFSD and Lilly

European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the Euro 2 million EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003 and renewed in 2006, the Fund has now reached a total commitment of Euro 3.8 million to fund its various activities, including research grants (see below) and fellowships (see page 24).

Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has contributed Euro 2.1 million towards the EFSD/Lilly Diabetes Research Programme, in the form of grants of up to Euro 100,000 each.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francesco Beguinot</td>
<td>University of Naples - Italy</td>
</tr>
<tr>
<td>Ingo Leibiger</td>
<td>Karolinska Institutet – Stockholm, Sweden</td>
</tr>
<tr>
<td>Martine Vaxillaire</td>
<td>Institut Pasteur Lille - France</td>
</tr>
<tr>
<td>Juleen Zierath</td>
<td>Karolinska Institutet – Stockholm, Sweden</td>
</tr>
</tbody>
</table>
EFSD
and
Merck Sharp & Dohme (MSD)

European Studies on
Beta Cell Function and Survival

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell glucotoxicity and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism.

Funding Commitment and Instruments

This partnership Programme was established in 2005 and renewed in 2007 for a total commitment of Euro 3.2 million, to be distributed in the form of grants, each of up to Euro 100,000.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Amar Abderrahmani: CHUV-Hospital - Lausanne, Switzerland
Stefano del Prato: University of Pisa - Italy
Valdemar Grill: University Hospital Trondheim - Norway
Noel Morgan: Peninsula Medical School - Plymouth, U.K
Hindrick Mulder: Lund University – Malmö, Sweden
Shanta Persaud: Kings College London - U.K
European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction

Background

Novartis is a world leader in the research and development of products to protect and improve health and well-being. Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz.

Plan

The EFSD/Novartis European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction was created in order to stimulate and accelerate European clinical research into all aspects of pancreatic islet dysfunction. This Programme targets the clinical physiology and natural history of pancreatic islet dysfunction as it pertains to diabetes and other dysglycaemic conditions, and accepts applications for both basic and clinical projects.

Funding Commitment and Instruments

A total of Euro 1.2 million has been made available to fund research grants up to Euro 200,000 each.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 200,000:

Per-Olof Berggren: Karolinska Institutet - Stockholm, Sweden
Steen Larsen: University of Copenhagen - Denmark
Geraldine Parnaud: University of Geneva - Switzerland
EFSD
and
Novo Nordisk A/S

European Clinical Research Programme in Adolescents with Type 2 Diabetes

Background
Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

Plan
The goals of the Programme are to promote the highest quality of clinical medical research in Europe and its associated countries applicable to type 2 diabetes in adolescents; to expedite the practical application of scientific advances in our understanding of the psycho-social conditions, aetiology, pathogenesis, treatment and prevention of type 2 diabetes and its complications in adolescents, and to encourage clinical translational research bridging bench and bedside.

Funding Commitments and Instruments
This is an extension of the original EFSD/Novo Nordisk Programme in Type 2 Diabetes, with a new combined total of **Euro 3 million** for grants, each of up to Euro 300,000.

Awards in 2007
Based on the recommendations of the Review Committee, the Programme Board made the following award of Euro 300,000:

John Nolan: Trinity College Dublin - Ireland
European Programmes for the Study of:

The Endocannabinoid System from Bench to Bedside
and
Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease

Background

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

EFSD and sanofi-aventis have created two European Programmes for studies in the following areas:

- The Endocannabinoid System from Bench to Bedside will focus on the integration of central and peripheral control of fuel and energy metabolism and its role in the pathophysiology of multiple cardiometabolic risk factors, including insulin resistance and type 2 diabetes. This programme supports both basic and clinical research.

- Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease supports clinical research in this field of study.

Funding Commitment and Instruments

A total of **Euro 2.1 million** has been made available to fund research grants in variable amounts of up to €300,000 each.
Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

The Endocannabinoid System from Bench to Bedside

This Programme funded grants totalling Euro 200,000 to the following:

Giovanni Marsicano:   Institut Magendie – Bordeaux, France
Hannele Yki-Järvinen: University of Helsinki - Finland

Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease

No awards were given in 2007. For 2008 this Programme has been renamed European Programme: Macrovascular Complications and Blood Glucose Abnormalities.
EFSD and Servier

European Research Programme on Vascular Complications of Type 2 Diabetes

Background

Servier is a research-based pharmaceutical company with an established reputation in diabetes research, therapeutics and education. Present in 135 countries worldwide, the company is proud to maintain a number of tight long-term collaborations with key diabetes organisations.

Plan

EFSD and Servier established the European Programme on Vascular Complications of Type 2 Diabetes to encourage quality new projects aimed at advancing current knowledge in this domain, with particular emphasis on projects that aim to clarify the molecular mechanisms of vascular complications in type 2 diabetes. These grants were intended to stimulate and accelerate European research into the vascular complications of type 2 diabetes.

Funding Commitment and Instruments

Starting in 2002 and renewed in 2005, the EFSD/Servier partnership has committed a total of Euro 2.1 million in the form of grants of up to Euro 100,000 each.

Awards in 2007

Based on the recommendations of the Review Committee, the Programme Board made the following awards of up to Euro 100,000 each:

- Kari Alitalo: University of Helsinki - Finland
- Hans-Peter Hammes: University of Heidelberg - Mannheim, Germany
- Fredrik Leeb-Lundberg: Lund University – Malmö, Sweden
- Paula Moreira: University of Coimbra - Portugal
European Foundation for the Study of Diabetes

EFSD

The Research Foundation of the
European Association for the Study of Diabetes

FELLOWSHIPS

AND

AWARDS

2007
Albert Renold Fellowships

Supported by an unrestricted educational grant from Merck Sharp & Dohme (MSD)

Albert Renold Fellowships, each of up to Euro 6,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months.

Albert Renold Fellowships are available throughout the year, and a decision is usually made within a few weeks of applying.

In 2007 the following Fellowships were awarded:

Chidum Ezenwaka: travelled to the German Diabetes Center – Düsseldorf, Germany
Daniel Andrade da Cunha: travelled to Free University Brussels - Belgium
Konstantinos Manolopolous: travelled to the University of San Diego - USA
Karl Jacobsen: travelled to Princetown Centre - New Jersey, USA
Chiara Guglielmi: travelled to Barts & the London - UK
Catherine Arden: travelled to University of Michigan - USA
Ioannis Kyrou: travelled to Warwick Medical School - UK
Onyegbutulem Henry Chijioke: travelled by University of Dresden - Germany
Lina Lauffer: travelled to University of Toronto - Canada
Manish Bharara: travelled to Union College - NY, USA
Kieran Rooney: travelled to Cambridge University - UK
Dany S Muller: travelled to INSERM Marseille - France
Dieter Rondas: travelled to University of Geneva - Switzerland
Emanuela Lapice: travelled to TUFTS University, - MA, USA
Kshitij Shankhedar: travelled to University of Manchester - UK
Charlotta Roos: travelled to Lund University - Malmö, Sweden
Apostolos Tapas: travelled to Oxford Centre - UK
Allagnat Florent: travelled to Free University Brussels - Belgium
AstraZeneca is one of the world's leading pharmaceutical companies, dedicated to the discovery, development, manufacturing and marketing of high quality, effective prescription medicines.

The EFSD/AstraZeneca Young Investigator Awards were established to promote increased European research in diabetes and support young scientists within Europe during their transition towards independence.

A total of Euro 300,000 was made available in 2007 for the Young Investigator Awards. Each Fellowship Award comprises Euro 50,000 per annum for a total of Euro 100,000, payable over two years.

In 2007 the following awards were made:

Gian Paolo Fadini: University of Padova - Italy  
Blanca Rubí: Pompeu Fabra University - Barcelona, Spain  
Ivana Stojanovic: Institute "Sinisa Stankovic" - Belgrade, Serbia
Travel Fellowships for Young Researchers from China

Supported by Bristol-Myers Squibb Company (BMS)

The objective of these Fellowships is to provide the opportunity for young researchers in China to visit a European institution.

Two Travel Fellowships, each of Euro 25,000, were made available to successful applicants from China. This amount is meant to support travel and living expenses for a period of time ranging from 3 to 6 months, to be spent in a European institution.

In 2007 the following Fellowships were awarded:

Qian Ge: Changqing University of Medical Sciences / University Catholique de Louvain - Belgium
Ning Li: Geneva University - Switzerland
The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

Two Fellowships of up to Euro 50,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships are available for the period 2006 – 2008 inclusive as part of the EFSD/Lilly European Diabetes Research Fund.

In 2007 the following Fellowships were awarded:

Aouatef Ait-Lounis: University of Geneva - Switzerland
Justo Sierra Johnson: Karolinska University Hospital - Stockholm, Sweden
EFSD
and
Pfizer Inc.

Resource Awards

Background

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. With a portfolio that includes five of the world's 20 top-selling medicines, Pfizer is helping to improve the lives of people the world over.

Plan

The aim of these awards is to allow for development of resources for diabetes research, which will be available on an open-access basis or at nominal cost to all researchers in the field in Europe. Examples might be products for research (e.g. gene microarrays), biological material (e.g. cell lines), a database or co-ordination and integration of samples/data from ongoing multi-centre endeavours (e.g. genetic screening).

Funding Instruments

A total of Euro 600,000 has been made available for this partnership Programme since its establishment in 2004.

Award in 2007

No resource award was given in 2007. This Programme will be replaced by the new EFSD/Pfizer European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes (see New Programmes 2008).
NEW PROGRAMMES

2008
EFSD
and the
Chinese Diabetes Society
and
Lilly

Research Fund

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Plan

This new partnership Fund will target collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Funding Commitment and Instruments

A total funding of **Euro 1.5 million** has been committed from 2008 – 2010. Two basic science research grants in the sum of up to Euro 100,000 and one clinical outcomes research grant in the sum of up to Euro 200,000 will be made available annually, for research to be carried out in China in collaboration with a European research institution. In addition, two Fellowship awards will be made available annually in an amount of up to Euro 50,000 each. Applications for Fellowships may be accepted from applicants from China for study in a recognised research institution in Europe.

Awards in 2008

The deadline for applications will be September 2008, with an anticipated award date of November 2008.
EFSD and Merck Sharp & Dohme (MSD)

European Studies on Islet Cell Function and Survival: Clinical Research Programme

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

EFSD and MSD have established this new Programme in order to stimulate and accelerate European research into clinical aspects of islet cell function and survival. Particular areas of interest include the following: alterations in islet cell mass/function in diabetes and obesity, non-invasive imaging of islet cells, mechanisms of beta cell dysfunction in type 2 diabetes, including beta cell gluco- and lipotoxicity, preservation or prevention of further loss of beta cell functional mass in individuals with impaired glucose tolerance, type 2 diabetes or early type 1 diabetes, methods for improving survival of transplanted islets or beta cells and genetic defects that elucidate beta cell dysfunction in type 2 diabetes.

Funding Commitment and Instruments

A total of Euro 2.7 million has been made available from 2008 – 2010, to be distributed through the award of fixed sum grants, each of up to Euro 100,000 per annum for a period up to three years, for a total individual funding amount not exceeding Euro 300,000.

Awards in 2008

The deadline for applications will be January 2008, with an anticipated award date of March 2008.
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes

**Background**

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. As part of its commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce cardiovascular risk, further our understanding of optimal treatment options, and ultimately improve the lives of people with diabetes.

**Plan**

This new research partnership has been established in order to better understand what best impacts cardiovascular risk reduction in patients with diabetes, and to evaluate the impact of CV risk reduction in diabetes using educational tools, programmes and strategies, risk assessment tools/screening and diagnostic procedures and/or clinical interventions.

**Funding Commitment and Instruments**

A total of **Euro 1.5 million** will be made available over the three year period 2008 – 2010. Funds will be distributed by way of research grants each of up to Euro 300,000 for projects of up to three years’ duration, as deemed appropriate for the project.

**Awards in 2008**

The deadline for applications will be March 2008, with an anticipated award date of June 2008.
EFSD Review Committee Members

EFSD is most grateful to the following colleagues who served in on the various review committees of the 2007 partnership programmes:

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amar Abderrahmani</td>
<td>CH</td>
</tr>
<tr>
<td>Arne Astrup</td>
<td>DK</td>
</tr>
<tr>
<td>Angelo Avogaro</td>
<td>I</td>
</tr>
<tr>
<td>Clifford Bailey</td>
<td>UK</td>
</tr>
<tr>
<td>Angelika Bierhaus</td>
<td>D</td>
</tr>
<tr>
<td>Henning Beck-Nielsen</td>
<td>DK</td>
</tr>
<tr>
<td>Polly Bingley</td>
<td>UK</td>
</tr>
<tr>
<td>Christian Boitard</td>
<td>F</td>
</tr>
<tr>
<td>Fatima Bosch</td>
<td>E</td>
</tr>
<tr>
<td>Luc Bouwens</td>
<td>B</td>
</tr>
<tr>
<td>Rémy Burcelin</td>
<td>F</td>
</tr>
<tr>
<td>Bernard Charbonnel</td>
<td>F</td>
</tr>
<tr>
<td>Miriam Cnop</td>
<td>B</td>
</tr>
<tr>
<td>Jens Sandahl Christiansen</td>
<td>DK</td>
</tr>
<tr>
<td>Jacqueline Dekker</td>
<td>NL</td>
</tr>
<tr>
<td>Stefano del Prato</td>
<td>I</td>
</tr>
<tr>
<td>Vincenzo di Marzo</td>
<td>I</td>
</tr>
<tr>
<td>Marc Donath</td>
<td>CH</td>
</tr>
<tr>
<td>Jorge Ferrer</td>
<td>E</td>
</tr>
<tr>
<td>Allan Flyvbjerg</td>
<td>DK</td>
</tr>
<tr>
<td>Ramon Gomis de Barbara</td>
<td>E</td>
</tr>
<tr>
<td>Valdemar Grill</td>
<td>N</td>
</tr>
<tr>
<td>Hans-Peter Hammes</td>
<td>D</td>
</tr>
<tr>
<td>Kristian Hanssen</td>
<td>N</td>
</tr>
<tr>
<td>Hans-Ulrich Häring</td>
<td>D</td>
</tr>
<tr>
<td>Stephan Herzig</td>
<td>D</td>
</tr>
<tr>
<td>Jean-Christophe Jonas</td>
<td>B</td>
</tr>
<tr>
<td>Peter Jones</td>
<td>UK</td>
</tr>
<tr>
<td>Fredrik Karpe</td>
<td>UK</td>
</tr>
<tr>
<td>Harald Klein</td>
<td>D</td>
</tr>
<tr>
<td>Markku Laakso</td>
<td>FIN</td>
</tr>
<tr>
<td>Martine Laville</td>
<td>F</td>
</tr>
<tr>
<td>Agnés Lehuen</td>
<td>F</td>
</tr>
<tr>
<td>Beat Lutz</td>
<td>D</td>
</tr>
<tr>
<td>Johannes Maassen</td>
<td>NL</td>
</tr>
<tr>
<td>Aldo Maggioni</td>
<td>I</td>
</tr>
<tr>
<td>Piero Marchetti</td>
<td>I</td>
</tr>
<tr>
<td>Michel Marre</td>
<td>F</td>
</tr>
<tr>
<td>Ulrich Müller</td>
<td>D</td>
</tr>
<tr>
<td>Andrea Natali</td>
<td>I</td>
</tr>
<tr>
<td>Michael Nauck</td>
<td>D</td>
</tr>
<tr>
<td>Kenneth Paterson</td>
<td>UK</td>
</tr>
<tr>
<td>John Pickup</td>
<td>UK</td>
</tr>
<tr>
<td>Massimo Porta</td>
<td>I</td>
</tr>
<tr>
<td>Romano Regazzi</td>
<td>I</td>
</tr>
<tr>
<td>Marian Rewers</td>
<td>USA</td>
</tr>
<tr>
<td>Gabriele Riccardi</td>
<td>I</td>
</tr>
<tr>
<td>Carani Sanjeevi</td>
<td>S</td>
</tr>
<tr>
<td>André Scheen</td>
<td>B</td>
</tr>
<tr>
<td>Giorgio Sesti</td>
<td>I</td>
</tr>
<tr>
<td>Åke Sjöholm</td>
<td>DK</td>
</tr>
<tr>
<td>Ulf Smith</td>
<td>S</td>
</tr>
<tr>
<td>Giatgen Spinas</td>
<td>CH</td>
</tr>
<tr>
<td>Philippe-Gabriel Steg</td>
<td>F</td>
</tr>
<tr>
<td>Coen Stehouwer</td>
<td>NL</td>
</tr>
<tr>
<td>Markus Stoffel</td>
<td>CH</td>
</tr>
<tr>
<td>Michael Stumvoll</td>
<td>D</td>
</tr>
<tr>
<td>Charles Thivolet</td>
<td>F</td>
</tr>
<tr>
<td>Tiina Tuomi</td>
<td>FIN</td>
</tr>
<tr>
<td>Hubert Vidal</td>
<td>F</td>
</tr>
<tr>
<td>Antonio Vidal-Puig</td>
<td>UK</td>
</tr>
<tr>
<td>Mark Walker</td>
<td>UK</td>
</tr>
<tr>
<td>Dan Ziegler</td>
<td>D</td>
</tr>
</tbody>
</table>
EFSD EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:
President: E. Ferrannini - Pisa
Vice President: U. Smith - Göteborg
Vice President: C. Boitard - Paris
Honorary Secretary: M. Stumvoll - Leipzig
Honorary Treasurer: G. Spinas - Zürich
Editor in Chief - Diabetologia: E. Gale – Bristol
Chairman PGESC: J. Nolan - Dublin

Chairman - EFSD: P.A. Halban – Geneva

Scientific Board:
S. Amiel - London
J. Ferrer - Barcelona
M. Walker – London

Executive Director: V. Jörgens - Düsseldorf
Administrators:
S. Köhnen - Düsseldorf
K. Sommer – Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0    Fax: + 49 211 75 84 69-29

www.EuropeanDiabetesFoundation.org

Email: Foundation@easd.org

Bank details
Europäische Stiftung für Diabetesforschung – EFSD
Dresdner Bank
Königsallee 37
40212 Düsseldorf, Germany

Account / Konto: 600 2146 00    Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547

The EFSD Accounts for the fiscal year 2006 were submitted to the German Inland Revenue. Following detailed
evaluation, a Certificate was issued endorsing the status of EFSD as a charity. This Certificate is held on file at the
EFSD office and a copy can be made available upon request.